NCT07314203 2026-01-02
SOP-XH-IRB
Fujian Medical University
Phase 3 Not yet recruiting
Clinical Trials
41 trialsNCT07311408 2025-12-31
SHR-2554
China Medical University, China
Phase 2 Recruiting
NCT06881017 2025-03-18
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
China Medical University, China
Phase 2 Not yet recruiting
NCT04863430 2025-02-21
Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach
Peking University
Phase 2 Withdrawn
NCT03878472 2024-12-16
Neoadjuvant Immunotherapy for Resectable Gastric Cancer
Qilu Hospital of Shandong University
Phase 2 Completed
NCT06485271 2024-07-03
A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer
Changzhi People's Hospital Affiliated to Changzhi Medical College
Recruiting
NCT06415669 2024-05-29
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT06385873 2024-05-13
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT04267549 2023-07-06
Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05853172 2023-05-10
Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04609176 2023-04-21
Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Peking University
Phase 2 Unknown
NCT05025033 2023-01-18
Chemotherapy Combined With Apatinib and PD-1 Antibody
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Completed
NCT05216237 2022-04-11
A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer
Affiliated Hospital of Qinghai University
Phase 2 Unknown
NCT03104283 2022-03-15
Apatinib for the Elderly Advanced Gastric Cancer
Affiliated Hospital of Qinghai University
Phase 2 Completed
NCT05095636 2021-10-27
Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer
Fudan University
Phase 2 Unknown
NCT05029453 2021-08-31
Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4 Unknown
NCT04934618 2021-06-22
A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT03154983 2020-12-09
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
Zhongnan Hospital
Phase 2 Unknown
NCT04338438 2020-11-10
Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer
Beijing Friendship Hospital
Phase 2 Completed
NCT04345783 2020-04-14
Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer
Beijing Friendship Hospital
Phase 2 Unknown
NCT03229096 2019-06-28
Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT03889626 2019-03-26
The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer
Fudan University
Phase 3 Unknown
NCT03598348 2018-07-26
Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer
Huazhong University of Science and Technology
Phase 3 Unknown
NCT02596256 2018-04-17
Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)
Chinese PLA General Hospital
Phase 2 Unknown
NCT02942329 2018-02-26
Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 1/2 Unknown
NCT03384511 2018-02-20
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Shandong Cancer Hospital and Institute
Phase 4 Completed
NCT03355612 2017-11-28
XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT02509806 2017-10-09
Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer
Hebei Medical University
Phase 2/3 Unknown
NCT02510469 2017-10-09
Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells
Hebei Medical University
Phase 2/3 Unknown
NCT03007446 2017-09-27
The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer
Chinese PLA General Hospital
Phase 2 Unknown
NCT03219593 2017-09-11
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
The First Affiliated Hospital of Bengbu Medical University
Phase 2 Unknown
NCT03276156 2017-09-08
Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer
Zhejiang Cancer Hospital
Phase 1 Unknown
NCT03271073 2017-09-01
A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer
Beijing Friendship Hospital
Phase 2 Unknown
NCT03144843 2017-05-09
Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.
Sun Yat-sen University
Phase 2 Unknown
NCT02537171 2016-08-02
Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 3 Unknown
NCT02529878 2016-07-26
Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer
The First Affiliated Hospital of Zhejiang Chinese Medical University
Phase 2 Unknown
NCT02776527 2016-05-20
A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 4 Unknown
NCT02485015 2016-02-19
The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
The First People's Hospital of Changzhou
Phase 2 Active not recruiting
NCT02409199 2015-11-18
A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer
Shanghai Zhongshan Hospital
Phase 2/3 Unknown
NCT02525237 2015-08-17
Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer
Qingdao Municipal Hospital
Phase 2 Unknown
NCT00970138 2011-07-12
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
Fudan University
Phase 2/3 Completed